Belite Bio, Inc
BLTEHealthcareNASDAQBiotechnology · Last scanned Jun 1, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Belite Bio, Inc focuses on Biotechnology services and products. Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. At a $5.78B market cap, Belite Bio, Inc ranks as a mid-cap company within healthcare. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Market Cap
$5.78B
Beta
-1.19
P/E (TTM)
—
P/E (Fwd)
152.69
EPS (TTM)
$-2.55
EPS (Fwd)
$0.94
ROE
-18.9%
ROA
-13.0%
Cash
—
Total Debt
$0
Free CF
—
52W Change
121.8%
Annual Financials
Cash vs Debt
Belite Bio, Inc carries $0 in total debt, a figure that investors should evaluate relative to the company's earnings power. Return on equity stands at -18.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
BLTE's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Belite Bio, Inc's trajectory.